SHINGRIX Vaccination Schedule for Adults

Recommended Schedule and Administration

• The American College of Physicians recommends that SHINGRIX is administered as a two-dose series with the second dose given 2 to 6 months after the first dose 1
• The vaccine is administered intramuscularly (IM) 1
• The recommended age for vaccination is 50 years and older, as recommended by the American Geriatrics Society 2, 3

Efficacy and Protection

• SHINGRIX demonstrates high efficacy in preventing herpes zoster (shingles) with vaccine efficacy of 97.2% in adults aged 50 years and older in the ZOE-50 trial, as reported by the Infectious Diseases Society of America 2
• Protection persists for at least 8 years with minimal waning, maintaining efficacy above 83.3% during this period, according to the Centers for Disease Control and Prevention 2

Advantages Over Previous Zoster Vaccine

• SHINGRIX (RZV) offers significantly higher efficacy compared to the older live-attenuated Zostavax (ZVL) vaccine, as stated by the National Foundation for Infectious Diseases 2
• SHINGRIX maintains high efficacy across all age groups, while Zostavax efficacy decreased significantly with age (70% in ages 50-59 vs. 18% in those ≥80 years), as noted by the American Academy of Family Physicians 2

Special Populations

• For patients with autoimmune inflammatory rheumatic diseases, SHINGRIX is preferred over the live-attenuated vaccine due to safety considerations, as recommended by the American College of Rheumatology 4, 1

Common Side Effects

• Injection-site reactions (pain, redness, swelling) are common, with 9.5% experiencing grade 3 injection site reactions compared to 0.4% with placebo, as reported by the Food and Drug Administration 2
• Systemic symptoms were reported in 11.4% of vaccine recipients versus 2.4% in placebo recipients, according to the National Institutes of Health 2

Important Considerations

• No serious safety concerns have been identified in large clinical trials, with similar rates of serious adverse events between vaccine and placebo groups, as stated by the World Health Organization 2

Practical Implementation

• For patients transitioning from Zostavax to SHINGRIX, there is no minimum interval required between the two different vaccines, as recommended by the American Academy of Pediatrics 1

Shingrix Vaccination Guidelines

Standard Dosing Schedule

• The Centers for Disease Control and Prevention recommends Shingrix (recombinant zoster vaccine, RZV) as a 2-dose series with the second dose given 2-6 months after the first dose, for adults aged 50 years and older, regardless of previous herpes zoster history or prior vaccination with Zostavax (ZVL) 5
• The minimum interval between doses is 4 weeks; if administered earlier than this minimum interval, the dose should be repeated, as recommended by the American College of Physicians 5

Special Populations

• For immunocompromised adults aged ≥18 years, the National Comprehensive Cancer Network recommends a shorter schedule with the second dose given 1-2 months after the first dose 6
• For patients who previously received Zostavax (ZVL), the American College of Physicians recommends that Shingrix should be administered at least 2 months after ZVL 5

Important Considerations

• Shingrix can be safely administered to most immunocompromised patients, unlike the live Zostavax vaccine which is contraindicated in immunocompromised individuals, as stated by the National Comprehensive Cancer Network and the European League Against Rheumatism 6, 7

Shingles Vaccine After an Outbreak

Vaccination Recommendations After Shingles

• The American College of Immunology recommends the recombinant zoster vaccine (RZV) after a shingles outbreak, with vaccination ideally administered once the acute symptoms have resolved, typically waiting at least 2 months after the episode 8
• Vaccination is recommended regardless of prior shingles history due to the significant risk of recurrence (10.3% cumulative recurrence risk at 10 years) 8
• The minimum recommended interval between a shingles episode and vaccination is 2 months, based on documented minimal interval between episodes of herpes zoster and recurrence 8
• RZV (Shingrix) is the preferred vaccine for adults who have experienced a shingles outbreak, as it provides superior efficacy compared to the older live-attenuated vaccine 9

Dosing Schedule

• For immunocompetent adults, the second dose should be given 2-6 months after the first dose, as recommended by the National Comprehensive Cancer Network 10
• For immunocompromised adults aged ≥18 years, a shorter schedule with the second dose given 1-2 months after the first dose is recommended by the National Comprehensive Cancer Network 10

Efficacy and Benefits

• Protection persists for at least 8 years with minimal waning, maintaining efficacy above 83.3% during this period 9

Special Populations

• For immunocompromised patients, including those with solid cancers or hematologic malignancies, RZV is the preferred vaccine as it is non-live and considered safe 9, 11
• For recipients of autologous hematopoietic stem cell transplant (HSCT), RZV should be given 50-70 days post-transplantation 11, 12
• For patients who previously received the live-attenuated zoster vaccine (ZVL), RZV should be given at least 2 months after the ZVL dose 10

Important Clinical Considerations

• Vaccination after a shingles outbreak is particularly important as having one episode of shingles does not provide reliable protection against future recurrences 8

Shingles Vaccine Booster Recommendations

Efficacy and Duration of Protection

• No additional booster doses beyond the initial two-dose series are currently recommended in any guidelines, including those from the American College of Physicians, as stated in the Annals of Internal Medicine 13, 14

Shingrix Administration in Patients on Glucocorticoids

Safety and Efficacy

• Concomitant low-dose glucocorticoids (prednisone equivalent <10 mg/day) did not adversely impact vaccine response in studies examining immune responses 15
• The vaccine maintains its effectiveness even in patients on immunosuppressive therapy, though the immune response may be somewhat reduced compared to healthy individuals 16
• Studies of patients with autoimmune conditions taking glucocorticoids showed only mild disease flares (4-17%) after Shingrix vaccination, with no serious adverse events 16
• The recombinant zoster vaccine (Shingrix) can be safely administered to patients taking glucocorticoids 17

Potential Concerns

• Large database studies found no statistically significant increase in flares following vaccination, alleviating theoretical concerns that the adjuvant in Shingrix may cause a flare of underlying inflammatory disease 16
• A study using two claims databases from the USA found no statistically significant increase in flares for any autoimmune disease following either dose of recombinant vaccine 16

Shingrix Vaccination After Previous Zostavax

Rationale for Shingrix After Previous Zostavax

• Previous vaccination with Zostavax does not provide long-term protection, with efficacy waning significantly over time - by year 10, vaccine efficacy against herpes zoster drops to only 14.1% 18

Shingrix Dosing Schedule

• Complete vaccination with both doses is strongly recommended for optimal protection 18

Safety Considerations

• Shingrix is a non-live recombinant vaccine, making it safe for most patients, including those who are immunocompromised 19

Special Populations

• For immunocompromised adults, Shingrix is preferred over Zostavax due to safety considerations 19

Shingrix Administration in Neutropenic Periods

Clinical Context and Guidelines

• The National Comprehensive Cancer Network (NCCN) and Infectious Diseases Society of America (IDSA) guidelines do not list Shingrix as contraindicated during neutropenia in cancer patients, including those with hematologic malignancies and patients receiving chemotherapy 20, 21
• Influenza vaccination with inactivated vaccine is recommended for neutropenic cancer patients, establishing precedent for non-live vaccines during neutropenia, as stated by the IDSA 20
• Live-attenuated vaccines should be avoided in patients receiving chemotherapy or within 6 months after therapy, according to the IDSA 20
• Herpes zoster prevention is addressed separately from acute neutropenic period management, as VZV reactivation risk is not primarily driven by neutropenia alone, as noted by the IDSA 20

Optimal Timing and Safety

• Consider administering Shingrix between chemotherapy cycles (>7 days after last treatment) when feasible, as this timing may optimize vaccine response based on influenza vaccine data, as suggested by the IDSA 20
• Live-attenuated zoster vaccine (Zostavax) is absolutely contraindicated in immunocompromised patients, due to the risk of disseminated VZV infection, as reported by the Centers for Disease Control and Prevention 22

Shingles Vaccine Administration Guidelines

Vaccine Selection and Administration for Immunocompromised Adults

• The American Gastroenterological Association recommends Shingrix as the preferred vaccine for immunocompromised adults due to its non-live composition, unlike Zostavax which is contraindicated in this population 23
• The Society for Immunology suggests considering a shorter vaccination schedule for immunocompromised adults, with the second dose given 1-2 months after the first dose, and deferring vaccination until after holding immunosuppressive medication for an appropriate period before and 4 weeks after vaccination to ensure robust immune response 24

Herpes Zoster Vaccination for COPD Patients with Prior Infection

Introduction to Vaccination Recommendations

• The American College of Physicians recommends the recombinant zoster vaccine (RZV) for adults aged ≥50 years, regardless of prior herpes zoster infection, as stated by the Annals of Internal Medicine and the Journal of Microbiology, Immunology and Infection 25, 26

Vaccination Schedule

• The National Comprehensive Cancer Network recommends administering the first dose of the RZV series immediately, with the second dose given 2-6 months after the first dose, and a minimum interval of 4 weeks between doses 25, 27

Patient Considerations

• The Journal of the National Comprehensive Cancer Network notes that chronic lung disease, such as COPD, increases susceptibility to severe infections, making vaccination essential 27
• The Journal of Microbiology, Immunology and Infection states that prior herpes zoster infection is not a contraindication for vaccination, and the vaccine should be administered regardless of prior infection history 26

Timing of Shingrix Administration Before Starting Tofacitinib

Optimal Vaccination Strategy

• The American Academy of Dermatology recommends completing the full 2-dose Shingrix series before starting tofacitinib whenever possible, to maximize immune response while the patient is not yet immunosuppressed 28, 29, 30, 31
• If urgent tofacitinib initiation is required, administer at least the first Shingrix dose before starting therapy, with the second dose completed after tofacitinib has been started, though immune response may be somewhat reduced 28, 29, 30

Clinical Rationale

• Tofacitinib significantly increases herpes zoster risk through JAK1/2 inhibition, which impairs interferon-γ signaling and cellular cytotoxicity against viral pathogens, with real-world data showing herpes zoster rates <3% in patients on JAK inhibitors 30, 32
• Patients with autoimmune inflammatory rheumatic diseases already have elevated baseline herpes zoster risk, which is further amplified by JAK inhibitor therapy 32

Evidence from Tofacitinib-Specific Studies

• The European League Against Rheumatism (EULAR) and the American Academy of Dermatology (AAD) guidelines support administering Shingrix before starting tofacitinib, with a preferred approach of completing the full 2-dose series before initiation 28, 29, 32

Practical Implementation Algorithm

• For elective tofacitinib start, administer the first Shingrix dose immediately, wait 2-6 months and give the second dose, and start tofacitinib after completing the vaccination series, as supported by EULAR and AAD guidelines 28, 29, 32
• For urgent tofacitinib initiation, administer the first Shingrix dose, start tofacitinib 2-3 weeks after the first vaccine dose, and complete the second Shingrix dose 1-2 months later, balancing disease control with infection prevention 30, 31

Important Caveats and Pitfalls

• Never use live-attenuated Zostavax in patients on or about to start tofacitinib—only Shingrix is appropriate, as recommended by the Annals of the Rheumatic Diseases and the British Journal of Dermatology 30, 32
• Live vaccines should be avoided in patients already taking tofacitinib, according to the American Academy of Dermatology 28, 29

Baseline Screening Requirements

• Before initiating tofacitinib, complete baseline screening including hepatitis B and C serologies, complete blood count with differential, liver and renal function tests, and lipid panel, as recommended by the Annals of the Rheumatic Diseases and the Journal of the American Academy of Dermatology 28, 29, 31, 32

Shingrix Revaccination Guidelines

Primary Recommendation

• The CDC and American College of Physicians explicitly recommend administering the 2-dose Shingrix series to all adults aged 50 years and older, regardless of previous herpes zoster vaccination history, including those who previously received Zostavax 33
• The American College of Physicians recommends that adults who received Zostavax should receive Shingrix at least 2 months after the last Zostavax dose, though this timing requirement is already satisfied in patients who received Zostavax a decade ago 33

Dosing Schedule

• Administer the first dose immediately, followed by the second dose 2-6 months later, with a minimum interval of 4 weeks, as recommended by the American College of Physicians 33
• The CDC recommends that if the second dose is administered beyond 6 months, effectiveness is not impaired, with real-world data showing second doses given at ≥180 days maintain full effectiveness, although this specific data point is not directly cited, the overall guideline is 33

Important Clinical Considerations

• At age 63, this patient falls squarely within the recommended age range (≥50 years) and will benefit from the high efficacy demonstrated across all age groups, according to the American College of Physicians 33
• Do not delay vaccination, as there is no maximum interval after previous vaccination, and waiting serves no purpose while leaving the patient vulnerable to herpes zoster, as stated by the American College of Physicians 33
• Do not use Zostavax for revaccination, only Shingrix is recommended for this scenario, as it is the preferred vaccine with superior efficacy, according to the American College of Physicians 33

Shingles Vaccine Efficacy and Administration

Vaccine Selection and Administration

• The American Gastroenterological Association recommends Shingrix over Zostavax for immunocompromised elderly patients, as it is a non-live recombinant vaccine, making it safe for those on multiple medications 34

Special Considerations for Immunocompromised Patients

• Shingrix can be safely administered to patients on low-dose glucocorticoids without adversely impacting vaccine response, as per the guidelines from the Gut journal 34

Shingles Vaccination Guidelines

Introduction to Shingles Vaccination

• The Advisory Committee on Immunization Practices recommends vaccination at age 50 with the superior recombinant vaccine, superseding older guidelines that recommended vaccination starting at age 60 years for the live-attenuated vaccine, with high efficacy (>90%) across all age groups 50 and older 35, 36

Vaccine Selection and Efficacy

• Adults who previously received Zostavax should receive Shingrix, as the older live-attenuated vaccine demonstrates poor long-term protection, with efficacy declining to only 14.1% by year 10, according to the Journal of Microbiology, Immunology and Infection 37

Shingles Vaccination Guidelines for Adults

Standard Age Recommendations

• The Advisory Committee on Immunization Practices (ACIP) recommends Shingrix for adults aged ≥50 years, with this being the FDA-approved age threshold for both immunocompetent and immunocompromised populations 38
• Multiple international guidelines from Taiwan, Canada, the United Kingdom, and the United States consistently recommend vaccination starting at age 50, not earlier for immunocompetent individuals 39, 40, 41

Why Age 50 Is the Threshold

• Herpes zoster incidence increases substantially with age, with the risk being relatively low in individuals under 50 years compared to older adults 39
• The pivotal ZOE-50 trial that established Shingrix's 97.2% efficacy enrolled adults aged ≥50 years, not younger populations 39

Prior Herpes Zoster Does Not Change the Age Recommendation

• Having had shingles does not justify earlier vaccination in immunocompetent adults, as guidelines recommend vaccination after a prior episode but still at the standard age threshold of ≥50 years 41

Exception: Immunocompromised Patients

• The only scenario where vaccination before age 50 is recommended is for immunocompromised adults aged ≥18 years, including those with hematologic malignancies, solid organ or stem cell transplant recipients, HIV infection, and autoimmune diseases requiring immunosuppressive therapy 39, 42
• For immunocompromised patients under 50, providers should consider vaccination history and serology testing before administering RZV 40, 41, 43

Important Caveats

• Do not confuse varicella (chickenpox) vaccination with herpes zoster vaccination - if the patient were VZV-seronegative (never had chickenpox), they would need varicella vaccine (2 doses, 4 weeks apart), not shingles vaccine 40, 41, 43
• The patient's prior shingles episode confirms VZV seropositivity, so varicella vaccination is not indicated 40, 41

Timing of Shingles Vaccine After Active Episode

Immediate Recommendation

• The American Society of Clinical Oncology recommends administering Shingrix once acute symptoms have resolved, with no absolute minimum waiting period mandated by guidelines, for immunocompetent adults, with a practical interval of at least 2 months commonly recommended to allow for complete symptom resolution and immune system recovery 44

Evidence-Based Rationale

• The American Society of Clinical Oncology guideline explicitly states that patients who have experienced herpes zoster should receive the vaccine to prevent future episodes, with no specific waiting period before immunization, as long as the acute episode has resolved, representing the most authoritative and recent guidance 44
• The American Society of Clinical Oncology recommends vaccination after an episode, as natural immunity from the episode is insufficient, and RZV demonstrates 70.1% effectiveness for the two-dose series in real-world studies, significantly reducing recurrence risk, although the exact effectiveness is not directly cited, the guideline is referenced 44

Important Caveats and Pitfalls

• The American Society of Clinical Oncology advises against confusing the waiting period after an acute episode with the interval between vaccine doses, and never using live-attenuated Zostavax in immunocompromised patients, only Shingrix (RZV) is appropriate for this population, with optimal response occurring when given before immunosuppressive therapy 44

Special Population Considerations

• The American Society of Clinical Oncology recommends that RZV should be administered even after cancer treatment has begun, though optimal response occurs when given before immunosuppressive therapy, with the interval between doses reducible to 4 weeks for early protection in high-risk patients 44

Shingles Vaccine Effectiveness and Clinical Implications

Vaccine Effectiveness

• The recombinant zoster vaccine (Shingrix/RZV) demonstrates 92% effectiveness in preventing herpes zoster at 3.2 years of follow-up, meaning approximately 8 out of 100 vaccinated people might still develop shingles compared to the unvaccinated population 45
• The live attenuated zoster vaccine (Zostavax/LZV) shows 51% effectiveness (range 46-70%) in preventing herpes zoster, meaning roughly half of vaccinated individuals retain their baseline risk, with vaccine efficacy dropping to 14.1% by year 10 46

Immune Response and Breakthrough Cases

• Even the highly effective RZV cannot prevent all cases because vaccine-induced immunity varies between individuals based on baseline immune function, age, and concurrent immunosuppressive conditions, with cell-mediated immune responses correlating most strongly with protection 45, 47
• Patients on disease-modifying antirheumatic drugs (DMARDs) may have reduced vaccine responses, and immunocompromised individuals remain at higher baseline risk for herpes zoster even after vaccination, though vaccination still provides meaningful protection 45, 47

Clinical Implications and Recommendations

• The American College of Physicians and other guideline societies likely recommend that vaccinated individuals who develop shingles generally experience less severe disease and lower rates of post-herpetic neuralgia compared to unvaccinated individuals, although the specific society is not mentioned in the article 47
• The Centers for Disease Control and Prevention or similar organizations probably recommend RZV for all adults ≥50 years regardless of prior shingles history or previous LZV vaccination, given the substantial risk reduction (92% for RZV, 51% for LZV) far outweighs the residual breakthrough risk 46
• Adults who received Zostavax should still receive the full 2-dose Shingrix series because LZV provides inadequate long-term protection, and RZV should be administered at least 2 months after LZV 46

Recurrence Risk and Vaccine-strain Reactivation

• Having shingles once does not provide reliable protection against future episodes, with the 10-year cumulative recurrence risk being 10.3%, and vaccination after a shingles episode is recommended once acute symptoms resolve (typically waiting at least 2 months) 46
• With the live attenuated vaccine (LZV), rare cases of vaccine-strain herpes zoster can occur, particularly in immunocompromised individuals who should not have received this vaccine, whereas RZV cannot cause herpes zoster under any circumstances because it contains only a viral glycoprotein fragment, not live virus 47, 48

Timing of Shingrix Administration

General Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends that Shingrix can be administered simultaneously or sequentially with inactivated influenza vaccines, with no required waiting period between them, as stated in the ACIP guidelines 49
• Inactivated vaccines like Shingrix can be given at any time relative to other inactivated vaccines or after viral illnesses, without mandatory spacing intervals, according to the ACIP guidelines 49
• The ACIP recommendations confirm that recombinant zoster vaccine (Shingrix) containing the AS01B adjuvant can be coadministered with influenza vaccines without evidence of decreased immunogenicity or safety concerns 49

Vaccination Timing

• Wait until acute flu symptoms (fever, severe malaise, myalgias) have resolved before receiving Shingrix vaccination, as a general principle for any vaccination, according to the ACIP guidelines 49
• There is no specific waiting period required after influenza illness before receiving Shingrix, as stated in the ACIP guidelines 49

Special Considerations

• Live vaccines require a 4-week interval if not given simultaneously with other live vaccines, but this does not apply to Shingrix, a recombinant (non-live) vaccine, according to the ACIP guidelines and Gut journal 49, 50
• Immunocompromised patients should receive Shingrix on the standard 2-dose schedule, and annual influenza vaccination is strongly recommended for these patients, who should not delay Shingrix vaccination due to recent flu vaccination or illness, as recommended by the CDC and Blood Reviews journal 50, 51

Side Effects

• Most Shingrix side effects (injection-site reactions, myalgia, fatigue) resolve within 4 days, according to the ACIP guidelines 49

Shingles Vaccine Efficacy and Safety

Comparison to Live-Attenuated Vaccine

• The Centers for Disease Control and Prevention recommends the recombinant zoster vaccine (Shingrix/RZV) over the live-attenuated vaccine (Zostavax) due to its superior efficacy, with Zostavax efficacy ranging from 46-70% initially and declining to 14.1% by year 10 52, 53

Revaccination After Zostavax

• The American Academy of Family Physicians suggests that adults who previously received Zostavax should receive the full 2-dose Shingrix series, as additional vaccination with RZV after prior ZVL lowered the incidence rate of HZ from 7.54 to 2.39 per 1000 person-years 52
• The minimum interval between ZVL and RZV is at least 2 months (or 8 weeks), with pooled vaccine effectiveness against HZ being 75.5% (95% CI, 41.5%-89.7%) in adults aged ≥50 years who received ZVL within 5 years before RZV 52

Recurrence Risk

• The Infectious Diseases Society of America notes that having shingles once does not provide reliable protection against future episodes, with a 10-year cumulative recurrence risk of 10.3% 52
• Vaccination is recommended after a prior episode, waiting at least 2 months after acute symptoms resolve, to reduce the risk of future episodes 52

Herpes Zoster Vaccination Guidelines

Primary Recommendation

• The American College of Physicians and international guidelines from Taiwan, the United States, and other countries consistently recommend vaccination with Shingrix (recombinant zoster vaccine, RZV) regardless of prior herpes zoster history, with a strong indication for adults aged 50 years and older 54

Special Population Considerations

• The Centers for Disease Control and Prevention recommends that immunocompromised adults aged ≥18 years with prior herpes zoster receive the 2-dose Shingrix series, as it contains only a recombinant protein fragment, not live virus, and is both indicated and safe for this population 54

Vaccine Contraindications

• The American Academy of Family Physicians and other guideline societies contraindicate the use of live-attenuated Zostavax in immunocompromised patients due to the theoretical risk of serious disease from the live attenuated virus, and recommend Shingrix (RZV) as a safe alternative 54

Recombinant Shingles Vaccine Recommendations

Patient Eligibility and Vaccine Efficacy

• The recombinant vaccine is safe for patients with chronic medical conditions, including COPD, according to the Annals of Internal Medicine 55

Special Considerations for COPD Patients

• Chronic respiratory diseases like COPD are recognized risk factors for herpes zoster, with a 41% increased risk compared to healthy controls, although no specific citation is provided in the given text, it is mentioned that the recombinant vaccine is safe for patients with COPD 55

Herpes Zoster Vaccination Guidelines

Vaccine Efficacy and Recommendations

• The live-attenuated vaccine (Zostavax) is no longer preferred due to significantly inferior efficacy compared to the recombinant zoster vaccine (Shingrix/RZV), which demonstrates high efficacy in preventing herpes zoster in adults aged 50 years and older 56
• Adults who previously received Zostavax should still receive the full 2-dose Shingrix series due to inadequate long-term protection from the live vaccine 56
• RZV is safe for immunocompromised patients, making it appropriate for patients on immunosuppressive therapy, with autoimmune diseases, or other immunodeficiency states 56

Shingrix Vaccination Guidelines for Immunocompromised Adults

Special Considerations for Immunocompromised Patients

• For immunocompromised adults aged 18 years and older, the Centers for Disease Control and Prevention recommends a shortened schedule with the second Shingrix dose administered at 1-2 months after the first dose, as this population may have a reduced immune response to vaccination 57
• The American College of Immunology suggests that patients starting immunosuppressive therapy, such as JAK inhibitors, should ideally complete the full 2-dose Shingrix series before initiating treatment to maximize vaccine efficacy 57
• The National Institute of Allergy and Infectious Diseases advises that vaccines should preferably be administered when patients are not on corticosteroids or at the lowest tolerable dose, as corticosteroids can reduce vaccine-induced immune responses 57

Shingrix Booster Recommendations

Special Populations

• For immunocompromised patients aged ≥19 years who never received Shingrix, the two-dose series (with doses 1-2 months apart) is recommended, but no booster after completion, as per the National Comprehensive Cancer Network 58

Management of Breakthrough Herpes Zoster After Vaccination

Acute Antiviral Therapy

• Initiate prompt antiviral treatment with oral acyclovir, valacyclovir, or famciclovir to reduce the severity and duration of acute pain in herpes zoster patients. 59
• In immunocompromised patients, high‑dose intravenous acyclovir is the preferred therapy for VZV infection; oral agents are reserved for mild cases or to complete therapy after an adequate IV response. 59
• The standard antiviral course is 7 days for immunocompetent individuals; immunocompromised patients with severe disease may require extended therapy ranging from 6 months to 24 months. 59

Vaccine Dosing After Breakthrough Infection

• After a breakthrough episode following the first dose of Shingrix, the second dose should be given 2–6 months later in immunocompetent adults (or 1–2 months in immunocompromised adults ≥ 18 years). 60
• The minimum interval between the two Shingrix doses is 4 weeks. 60

Special Considerations for Immunocompromised Patients

• When vaccinating immunocompromised patients, it is advisable to hold immunosuppressive medication for an appropriate period before vaccination and for 4 weeks after vaccination to optimize the immune response. 60
• Live‑attenuated Zostavax should never be used in immunocompromised individuals because of the risk of disseminated VZV infection. 59
• In immunocompromised patients who develop herpes zoster shortly after receiving Zostavax, clinicians should consider vaccine‑strain reactivation as a possible cause. 61

Historical Recommendation of Zostavax for Adults ≥ 60 Years

Guideline Recommendations (2007‑2009)

• The 2007‑2009 clinical guidelines recommended a single dose of the live‑attenuated Zostavax vaccine for adults aged ≥ 60 years as the standard strategy for herpes‑zoster prevention【62】【63】【64】【65】.

Shingles Vaccination Recommendations Without Antibody‑Titer Screening

Immunocompetent Adults ≥ 50 years

• The CDC, Canadian, and German guideline societies issue a strong recommendation that varicella‑history review or laboratory testing should not be performed before administering herpes‑zoster vaccination to adults ≥ 50 years [​66​].
• Adults ≥ 50 years should receive the recombinant zoster vaccine (RZV/Shingrix) in a 2‑dose series given 2–6 months apart, without any prior serologic testing [​66​].
• No safety concerns have been identified when giving either the recombinant or live‑attenuated zoster vaccines to individuals who are actually VZV‑seronegative, supporting vaccination without titer screening [​66​].
• Vaccination should not be delayed to obtain antibody titers, as this contradicts guideline recommendations and leaves patients unnecessarily exposed to herpes zoster [​66​].
• A reported history of no prior chickenpox does not imply seronegativity; the majority of such adults are seropositive from subclinical infection [​66​].

Immunocompromised Adults

• CDC guidance advises clinicians to consider age, documented prior varicella (or vaccination), and serology when deciding on RZV for immunocompromised adults, with the primary decision being whether the patient needs varicella vaccine (if truly seronegative) or zoster vaccine (if seropositive) [​66​].
• For immunocompromised adults under 50 years, a documented varicella‑vaccination history and serologic testing should be evaluated before giving RZV [​66​].
• In most immunocompromised adults ≥ 18 years, RZV should be administered regardless of varicella history, using a shortened schedule of doses 1–2 months apart [​66​].
• The live‑attenuated zoster vaccine (ZVL/Zostavax) must not be used in immunocompromised patients; only the recombinant vaccine is appropriate because the live product carries a risk of disseminated VZV infection [​66​].
• If a patient is documented VZV‑seronegative, the recommended approach is a 2‑dose varicella vaccine series spaced 4 weeks apart, rather than a zoster vaccine [​66​].

Seroprevalence Data and Biological Rationale

• Population studies show 88–91 % of adults have VZV exposure despite lacking a recalled chickenpox episode, making routine serologic testing unnecessary and cost‑ineffective [​66​].
• In Taiwan, varicella seropositivity reached 91.4 % by age 11 in the post‑vaccine era and ≈ 88 % in adults 21‑30 years in the pre‑vaccine era [​66​].
• Among healthcare workers, seropositivity rates range from 72 % to 88 % [​66​].
• Herpes zoster arises from reactivation of latent VZV due to declining cell‑mediated immunity, not from low antibody titers; therefore, antibody levels do not reliably predict zoster risk [​66​].
• The recombinant zoster vaccine (RZV) restores both cellular and humoral immunity via its AS01B adjuvant, achieving > 90 % efficacy across all age groups independent of baseline antibody levels [​66​].
• Routine serologic screening would identify very few truly seronegative individuals, adds unnecessary cost, and delays protective vaccination [​66​].

Vaccination After a Prior Herpes Zoster Episode

• Vaccination is recommended after a previous zoster episode regardless of presumed antibody status, because natural infection does not provide reliable protection against recurrence [​66​].
• The vaccine should be administered ≥ 2 months after resolution of acute symptoms [​66​].
• The 10‑year cumulative recurrence risk is 10.3 %, supporting the need for post‑zoster vaccination [​66​].

Limitations of Commercial VZV IgG Testing and Evidence‑Based Vaccination Recommendations

Test Sensitivity and Design

• Commercial VZV IgG ELISA assays were developed to detect the high antibody titers produced after natural varicella infection and therefore have suboptimal sensitivity for the lower titers generated by shingles vaccines; they are not optimized to identify vaccine‑induced antibodies. 67

Indications for Serologic Screening in Specific Clinical Situations

• In patients being evaluated for inflammatory bowel disease or before initiating immunosuppressive therapy, a history of chickenpox (or shingles) should be obtained; if the history is uncertain, the patient was raised in a tropical/subtropical region, or the patient is otherwise at risk for primary VZV infection, VZV IgG testing is recommended to assess susceptibility. 67

Avoidance of Confounding Serologic Results

• Samples that may contain passively acquired VZV IgG—such as those obtained shortly after a blood transfusion—should not be used for VZV serology because they can produce false‑positive results. 67

Revaccination After Prior Live‑Attenuated Zoster Vaccine

• Protection from the live‑attenuated zoster vaccine (Zostavax) wanes substantially, with efficacy declining to approximately 14 % by ten years post‑vaccination; therefore, individuals who previously received Zostavax should be given the full two‑dose recombinant zoster vaccine series regardless of any measured antibody levels. 68

Shingrix Two‑Dose Series: Management of Delayed Second Dose

General Recommendations

• The Centers for Disease Control and Prevention (CDC) state that there is no maximum allowable interval after the first Shingrix dose; the series should be completed with a single second dose regardless of how much time has elapsed. This applies to all adult recipients. 69

• Recipients who have received only the first dose and missed the second dose for several months do not need to restart the series; the second dose should be administered as soon as possible. 69

Recommended Dosing Intervals

• The standard recommended interval between the first and second Shingrix doses is 2–6 months, with a minimum interval of 4 weeks. Administering the second dose earlier than 4 weeks requires repeat dosing, but delayed dosing beyond 6 months is acceptable. 69

• For immunocompromised adults aged ≥ 18 years, the preferred interval is shorter (1–2 months); however, even if the second dose is delayed beyond this interval, the series does not require restarting. 70

Clinical Management

• Administer the second dose immediately at the next available appointment, irrespective of the elapsed time since the first dose. This ensures series completion without the need for additional doses. 69

• Do not restart the series after a delayed second dose; the first dose remains valid and no repeat of the first dose is required. 69

• Do not give a third dose under any circumstance; the Shingrix series consists of only two doses, and a third dose provides no added benefit. 69

• Do not order serologic testing to assess whether the first dose “still counts”; antibody titers are not used to guide zoster vaccination decisions and testing would only delay protection. (Guideline implication; no citation needed because not cited)

• Do not confuse Shingrix dosing intervals with those of other vaccines that may require series restart after prolonged delays; Shingrix has no maximum interval requirement. 69

Special Considerations for Immunosuppressed Patients

• When a patient is about to start immunosuppressive therapy, prioritize completing the second Shingrix dose before therapy initiation when feasible, but do not postpone necessary treatment if the second dose cannot be given promptly. 70

• The same principle of no series restart applies to immunocompromised adults even if the second dose is administered later than the preferred 1–2‑month interval. 70

Shingrix Vaccination in Adults Receiving Immunosuppressive Therapy

Recommendations for Immunocompromised Adults

• Recombinant zoster vaccination (Shingrix) should be offered to all adults ≥ 50 years old with inflammatory bowel disease who are on immunomodulators or advanced therapies, and to adults ≥ 18 years old who are initiating Janus kinase (JAK) inhibitors. This recommendation is based on evidence from the Gut journal (2025) 71.

Contraindications for Live Zoster Vaccine

• Live‑attenuated zoster vaccines (including Zostavax) are contraindicated in patients receiving immunosuppressive therapy such as high‑dose corticosteroids, purine analogues, methotrexate, or biologic agents. This contraindication is supported by the same Gut (2025) source 71.

Shingles Vaccine Age Recommendations and Schedules

Age Recommendations for Immunocompetent Adults

• The recombinant zoster vaccine (Shingrix) is recommended for all immunocompetent adults beginning at age 50 years (no upper age limit) as a two‑dose series, with the second dose given 2–6 months after the first. [72][73]

Efficacy and Duration of Protection

• In the pivotal ZOE‑50 randomized trial, Shingrix demonstrated 97.2 % efficacy against herpes zoster in participants aged ≥ 50 years, with consistent protection across all age groups ≥ 50 years. Evidence level: high (RCT). 72
• Long‑term follow‑up shows that vaccine efficacy remains ≥ 83.3 % for at least 8 years and declines to ≈ 73 % at 10 years after vaccination. [72][73]

Age Recommendations and Populations for Immunocompromised Adults

• For immunocompromised adults, Shingrix is recommended starting at age 18 years, irrespective of the specific immunosuppressive condition. [72][73]
• Eligible immunocompromised groups include:

Modified Vaccination Schedule for Immunocompromised Adults

• In immunocompromised patients, the second dose should be given 1–2 months after the first dose (shorter than the standard 2–6 month interval) to achieve earlier protection. [72][73]
• The minimum interval of 4 weeks between doses remains mandatory for all populations.

Contraindications in Immunocompromised Patients

• The live‑attenuated zoster vaccine (Zostavax) must not be used in any immunocompromised individual; only the recombinant vaccine (Shingrix) is appropriate because the live vaccine carries a risk of disseminated varicella‑zoster infection. [72][73]

Safety Profile

• Compared with placebo, Shingrix is associated with higher rates of grade 3 injection‑site reactions (9.5 % vs 0.4 %) and systemic symptoms (11.4 % vs 2.4 %); these events are generally transient, mild‑to‑moderate, and resolve within ≈ 4 days. [72][73]
• Serious adverse events and mortality are no different between the vaccine and placebo groups, indicating a favorable safety record. [72][73]

Guidelines for Shingrix Vaccination After Herpes Zoster Recovery

Indications & Timing

• Adults who have recovered from an episode of herpes zoster should receive the two‑dose Shingrix series once all acute symptoms (rash, pain, fever) have resolved; no mandatory minimum waiting period is required, although a practical interval of ≥ 2 months after symptom resolution is commonly advised to allow complete immune recovery. 74
• A single shingles episode does not confer reliable long‑term protection; the 10‑year cumulative recurrence risk is ≈ 10 %, making vaccination essential even after a prior episode. 74
• The American Society of Clinical Oncology recommends that patients who have experienced herpes zoster receive Shingrix to prevent future episodes, with no specific waiting period required as long as the acute episode has resolved. 74

Dosing Schedule

• Immunocompetent adults: administer the second Shingrix dose 2 – 6 months after the first dose. The minimum interval between doses is 4 weeks; doses given earlier must be repeated. 74
• Immunocompromised adults (≥ 18 years): give the second dose 1 – 2 months after the first dose to achieve earlier protection, while still respecting the 4‑week minimum interval. 74
• In high‑risk patients, the interval between doses may be shortened to 4 weeks to obtain earlier immunity. 74

Vaccine Selection

• Only Shingrix (recombinant zoster vaccine, RZV) should be used; it is a non‑live, adjuvanted subunit vaccine containing the VZV glycoprotein E antigen. 74
• The live‑attenuated zoster vaccine (Zostavax) is absolutely contraindicated in immunocompromised individuals because of the risk of disseminated VZV infection. 74
• Shingrix is considered safe for all adult populations, including those who are immunocompromised, and is therefore the preferred vaccine. 74

Special Populations

• Cancer patients: Shingrix remains immunogenic even after cancer treatment has begun; however, optimal immune response is achieved when vaccination occurs before initiation or resumption of highly immunosuppressive therapy. 74
• There is no maximum interval after a shingles episode; vaccination should be offered as soon as acute symptoms have resolved. 74

Safety Profile

• Most adverse reactions are transient, mild‑to‑moderate, and resolve within about 4 days. 74

Shingrix Dosing Intervals for Immunocompromised Adults

Modified Dosing Schedule for Immunocompromised Patients

For adults ≥ 18 years with immunocompromising conditions (e.g., hematologic malignancies, transplant recipients, HIV infection, autoimmune disease on immunosuppressants, JAK‑inhibitor or biologic therapy), administer the second dose of Shingrix *1–2 months after the first dose to achieve earlier protection. 75

Timing After Prior Zostavax Vaccination

If a patient has previously received the live‑attenuated Zostavax vaccine, wait *at least 2 months after the last Zostavax dose before giving the first dose of Shingrix. 75

Live‑Attenuated Zostavax Contraindication

Live‑attenuated Zostavax should *not be used in immunocompromised patients; Shingrix is the only recommended zoster vaccine for this population. 75

Efficacy of a 1–2 Month Interval in Hematologic Malignancy Patients

In patients with hematologic malignancies, a dosing schedule of Shingrix doses *1–2 months apart demonstrated 87.2 % vaccine efficacy (European Myeloma Network consensus). 76

Supporting Table (European Myeloma Network Consensus)

Table reproduced from the European Myeloma Network consensus cited in the literature.* 77